| SEGMENT INFORMATION |
NOTE
12 – SEGMENT INFORMATION
We
manage our business activities on a consolidated basis and operate as a 1 single
operating segment dedicated to developing and marketing products for various medical conditions. We derive our revenue from product
sales of the AlloRx™ , research and development, and InfiniVive product lines, . The accounting policies of the segment are
the same as those described in Note 1 – Nature of Organization and Summary of Significant Accounting Policies.
Our
Chief Operating Decision Maker (“CODM”) is our Chief Executive Officer, Chris Furman. The CODM uses net loss, as reported
in our consolidated statements of operations, in evaluating the performance of the segment and determining how to allocate our resources
as a whole. The CODM does not review assets in evaluating the results of the segment, and therefore, such information is not presented.
The
following table presents the operating results of the segment:
SCHEDULE OF OPERATING RESULTS OF THE SEGMENT
| | |
Three
Months Ended July
31, 2026 | | |
Three
Months Ended July
31, 2025 | |
| Revenues | |
$ | 570,464 | | |
$ | 608,643 | |
| Less Significant Segment Expenses: | |
| | | |
| | |
| Cost of Sales | |
| (144,638 | ) | |
| (69,612 | ) |
| Total Compensation and Benefits Cost | |
| (499,148 | ) | |
| (486,506 | ) |
| Research and Development | |
| (277,128 | ) | |
| (119,210 | ) |
| Impairment Expense | |
| | | |
| | |
| All Other Operating Expenses (Excluding Depreciation, Amortization and Stock Based
Compensation) (a) | |
| (624,820 | ) | |
| (509,174 | ) |
| Other Segment Items: | |
| | | |
| | |
| Depreciation, Amortization and Stock-Based Compensation | |
| (282,839 | ) | |
| (314,254 | ) |
| Interest Expense | |
| (108,460 | ) | |
| (859,591 | ) |
| Other Income (Expense), Net | |
| (7,177,168 | ) | |
| 51,166 | |
| | |
| | | |
| | |
| Consolidated Net Loss | |
$ | (8,543,737 | ) | |
$ | (1,698,538 | ) |
| |
(a) |
All
other operating expenses included in consolidated net loss include professional fees, lease expenses, insurance costs, travel and
entertainment expenses, and all other selling, general and administrative expenses. |
The
following table presents the operating results of the segment:
| | |
Nine
months Ended July
31, 2026 | | |
Nine
months Ended July
31, 2025 | |
| Revenues | |
$ | 1,546,176 | | |
$ | 1,570,101 | |
| Less Significant Segment Expenses: | |
| | | |
| | |
| Cost of Sales | |
| (365,899 | ) | |
| (297,531 | ) |
| Total Compensation and Benefits Cost | |
| (1,353,927 | ) | |
| (1,260,668 | ) |
| Research and Development | |
| (556,155 | ) | |
| (415,524 | ) |
| Impairment Expense | |
| (99,700 | ) | |
| - | |
| All Other Operating Expenses (Excluding Depreciation, Amortization and Stock Based
Compensation) (a) | |
| (1,846,531 | ) | |
| (2,291,894 | ) |
| Other Segment Items: | |
| | | |
| | |
| Depreciation, Amortization and Stock-Based Compensation | |
| (846,371 | ) | |
| (1,122,427 | ) |
| Interest Expense | |
| (1,120,155 | ) | |
| (1,359,244 | ) |
| Other Income (Expense), Net | |
| (6,561,368 | ) | |
| (834,799 | ) |
| | |
| | | |
| | |
| Consolidated Net Loss | |
$ | (11,203,930 | ) | |
$ | (6,011,986 | ) |
| |
(a) |
All
other operating expenses included in consolidated net loss include professional fees, lease expenses, insurance costs, travel and
entertainment expenses, and all other selling, general and administrative expenses. |
|